SG11201509265SA - Avoiding narcolepsy risk in influenza vaccines - Google Patents
Avoiding narcolepsy risk in influenza vaccinesInfo
- Publication number
- SG11201509265SA SG11201509265SA SG11201509265SA SG11201509265SA SG11201509265SA SG 11201509265S A SG11201509265S A SG 11201509265SA SG 11201509265S A SG11201509265S A SG 11201509265SA SG 11201509265S A SG11201509265S A SG 11201509265SA SG 11201509265S A SG11201509265S A SG 11201509265SA
- Authority
- SG
- Singapore
- Prior art keywords
- narcolepsy
- avoiding
- risk
- influenza vaccines
- influenza
- Prior art date
Links
- 229960003971 influenza vaccine Drugs 0.000 title 1
- 201000003631 narcolepsy Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361822228P | 2013-05-10 | 2013-05-10 | |
| US201361859113P | 2013-07-26 | 2013-07-26 | |
| US201361862807P | 2013-08-06 | 2013-08-06 | |
| EP13181429 | 2013-08-23 | ||
| EP14158999 | 2014-03-11 | ||
| PCT/EP2014/059672 WO2014180999A1 (fr) | 2013-05-10 | 2014-05-12 | Évitement du risque de narcolepsie dans les vaccins contre la grippe |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201509265SA true SG11201509265SA (en) | 2015-12-30 |
Family
ID=51660716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201509265SA SG11201509265SA (en) | 2013-05-10 | 2014-05-12 | Avoiding narcolepsy risk in influenza vaccines |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20140335116A1 (fr) |
| EP (1) | EP2801372A3 (fr) |
| JP (1) | JP2016521282A (fr) |
| KR (1) | KR20160030097A (fr) |
| CN (1) | CN105828835A (fr) |
| AU (1) | AU2014264501A1 (fr) |
| BR (1) | BR112015028314A2 (fr) |
| CA (1) | CA2911296A1 (fr) |
| MX (1) | MX2015015428A (fr) |
| SG (1) | SG11201509265SA (fr) |
| WO (1) | WO2014180999A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140335116A1 (en) | 2013-05-10 | 2014-11-13 | Novartis Ag | Avoiding narcolepsy risk in influenza vaccines |
| US20210188983A1 (en) * | 2016-02-18 | 2021-06-24 | Universite De Montpellier | Polypeptides for preparing drug conjugates capable of promoting apoptosis in a cell expressing an orexin receptor |
| CN111511800B (zh) | 2017-10-30 | 2023-11-28 | 武田药品工业株式会社 | 灭活脂包膜病毒的环境相容性去污剂 |
| US11428638B2 (en) | 2018-01-12 | 2022-08-30 | The Regents Of The University Of California | Spectroscopic biological material characterization |
| WO2020132063A1 (fr) * | 2018-12-19 | 2020-06-25 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions et méthodes pour diagnostiquer la narcolepsie |
| CN111803625B (zh) * | 2020-09-09 | 2020-12-18 | 天津中逸安健生物科技有限公司 | 一种亚单位流感疫苗裂解剂及其应用 |
| WO2025021112A1 (fr) * | 2023-07-24 | 2025-01-30 | 佳吾益(北京)科技有限公司 | Cellule modifiée pour développer un néo-antigène de cmh |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0114787B1 (fr) | 1983-01-25 | 1991-09-25 | Ciba-Geigy Ag | Dérivés peptidiques |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
| WO1995011700A1 (fr) | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Emulsions submicroniques utilisees comme adjuvants de vaccin |
| DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| DE19612967A1 (de) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
| TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| US20030130212A1 (en) | 1999-01-14 | 2003-07-10 | Rossignol Daniel P. | Administration of an anti-endotoxin drug by intravenous infusion |
| DE60036952T2 (de) | 1999-09-24 | 2008-08-07 | Glaxosmithkline Biologicals S.A. | Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung |
| AU2001236042B9 (en) | 2000-03-03 | 2006-06-29 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell |
| GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
| US20040071734A1 (en) | 2001-02-23 | 2004-04-15 | Nathalie Garcon | Novel vaccine |
| EP1361889A1 (fr) | 2001-02-23 | 2003-11-19 | GlaxoSmithKline Biologicals S.A. | Nouveau vaccin |
| MY134424A (en) | 2001-05-30 | 2007-12-31 | Saechsisches Serumwerk | Stable influenza virus preparations with low or no amount of thiomersal |
| JP2005533057A (ja) | 2002-06-13 | 2005-11-04 | ニューヨーク・ユニバーシティ | 合成ｃ−糖脂質、ならびに癌、感染性疾患および自己免疫疾患を処置するための合成ｃ−糖脂質の使用 |
| US7771726B2 (en) | 2003-10-08 | 2010-08-10 | New York University | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases |
| KR20110132416A (ko) | 2004-04-05 | 2011-12-07 | 화이자 프로덕츠 인코포레이티드 | 미세유체화된 수중유 유화액 및 백신 조성물 |
| WO2005113756A1 (fr) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Methode |
| WO2005113758A1 (fr) | 2004-05-20 | 2005-12-01 | Id Biomedical Corporation | Procédé pour la fabrication d’un vaccin contre la grippe |
| US7670837B2 (en) | 2004-12-23 | 2010-03-02 | Medimmune, Llc | Non-tumorigenic MDCK cell line for propagating viruses |
| GB0506001D0 (en) * | 2005-03-23 | 2005-04-27 | Glaxosmithkline Biolog Sa | Novel use |
| KR20160064249A (ko) * | 2005-03-23 | 2016-06-07 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Ｃｄ4 ｔ－세포 및/또는 개선된 ｂ－메모리 세포 반응을 유도하는 인플루엔자 바이러스 및 수중유 에멀젼 애주번트의 용도 |
| FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
| US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
| US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
| TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯 |
| DE602006019629D1 (de) | 2005-11-01 | 2011-02-24 | Novartis Vaccines & Diagnostic | Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna |
| DE202006021242U1 (de) | 2005-11-04 | 2014-01-29 | Novartis Vaccines And Diagnostics S.R.L. | Emulsionen mit freiem wässrigen Phasen Tensid als Adjuvans für Spalt-Grippeimpfstoffe |
| FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| CA2656427C (fr) | 2006-07-07 | 2014-12-09 | Gilead Sciences, Inc. | Modulateurs du recepteur tlr7 (toll-like receptor 7) |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| US20100183667A1 (en) | 2006-10-12 | 2010-07-22 | Glaxo Smithkline Biologicals S.A. | Vaccine Comprising an Oil in Water Emulsion Adjuvant |
| WO2008047174A1 (fr) | 2006-10-18 | 2008-04-24 | Centre National De La Recherche Scientifique | Analogues de l'alpha-galactocéramide, leurs procédés de fabrication, composés intermédiaires utiles dans ces procédés, et compositions pharmaceutiques les contenant |
| CN101553252A (zh) | 2006-12-06 | 2009-10-07 | 诺华有限公司 | 包含来自于四株流感病毒的抗原的疫苗 |
| PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
| KR101208778B1 (ko) | 2008-03-03 | 2012-12-05 | 노파르티스 아게 | Ｔｌｒ 활성 조정제로서의 화합물 및 조성물 |
| CN103396415B (zh) | 2008-03-24 | 2016-08-10 | 4Sc股份有限公司 | 新的取代的咪唑并喹啉化合物 |
| ES2438496T3 (es) | 2008-08-01 | 2014-01-17 | Ventirx Pharmaceuticals, Inc. | Formulaciones de agonistas de receptores de tipo toll y su uso |
| CN107365751B (zh) * | 2008-12-16 | 2021-07-09 | 纳米医疗公司 | 流感疫苗的生产 |
| EP2435066B1 (fr) * | 2009-05-29 | 2013-11-20 | Novartis AG | Dosage des hemagglutinines du virus de la grippe |
| JO3257B1 (ar) | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
| GB0918830D0 (en) | 2009-10-27 | 2009-12-09 | Glaxosmithkline Biolog Niederl | Process |
| CN102905703B (zh) | 2010-03-23 | 2016-09-28 | 诺华股份有限公司 | 作为tlr2激动剂用于治疗感染、炎症、呼吸疾病等的化合物(基于半胱氨酸的脂肽)和组合物 |
| CN105999275A (zh) | 2010-09-01 | 2016-10-12 | 诺华有限公司 | 免疫增强剂吸附不溶性金属离子 |
| US20140335116A1 (en) | 2013-05-10 | 2014-11-13 | Novartis Ag | Avoiding narcolepsy risk in influenza vaccines |
-
2014
- 2014-05-12 US US14/275,373 patent/US20140335116A1/en not_active Abandoned
- 2014-05-12 JP JP2016512393A patent/JP2016521282A/ja active Pending
- 2014-05-12 KR KR1020157034963A patent/KR20160030097A/ko not_active Withdrawn
- 2014-05-12 CN CN201480039584.1A patent/CN105828835A/zh active Pending
- 2014-05-12 WO PCT/EP2014/059672 patent/WO2014180999A1/fr not_active Ceased
- 2014-05-12 CA CA2911296A patent/CA2911296A1/fr not_active Abandoned
- 2014-05-12 EP EP14167980.3A patent/EP2801372A3/fr not_active Withdrawn
- 2014-05-12 BR BR112015028314A patent/BR112015028314A2/pt not_active Application Discontinuation
- 2014-05-12 MX MX2015015428A patent/MX2015015428A/es unknown
- 2014-05-12 AU AU2014264501A patent/AU2014264501A1/en not_active Abandoned
- 2014-05-12 SG SG11201509265SA patent/SG11201509265SA/en unknown
-
2016
- 2016-10-04 US US15/284,624 patent/US20170216425A1/en not_active Abandoned
-
2019
- 2019-03-06 US US16/293,867 patent/US20190184007A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014264501A1 (en) | 2015-12-10 |
| CN105828835A (zh) | 2016-08-03 |
| US20140335116A1 (en) | 2014-11-13 |
| KR20160030097A (ko) | 2016-03-16 |
| US20190184007A1 (en) | 2019-06-20 |
| US20170216425A1 (en) | 2017-08-03 |
| EP2801372A2 (fr) | 2014-11-12 |
| BR112015028314A2 (pt) | 2017-09-19 |
| EP2801372A3 (fr) | 2015-02-18 |
| CA2911296A1 (fr) | 2014-11-13 |
| MX2015015428A (es) | 2016-07-18 |
| JP2016521282A (ja) | 2016-07-21 |
| WO2014180999A1 (fr) | 2014-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276210A (en) | MERS-COV vaccine | |
| IL279395A (en) | A vaccine | |
| IL235890A0 (en) | vaccine | |
| SI3077519T1 (sl) | CMV cepiva | |
| SG11201505889RA (en) | Multivalent glycoconjugate vaccines | |
| GB201403828D0 (en) | Pulmonary delivery device | |
| ZA201508642B (en) | Malaria vaccine | |
| GB201303627D0 (en) | Thermal Model | |
| GB201318084D0 (en) | Malaria vaccination | |
| GB201315946D0 (en) | Oncology vaccine | |
| AU356420S (en) | Blower | |
| GB201223386D0 (en) | Vaccine | |
| GB201301085D0 (en) | Glycoconjugate Vaccine | |
| SG11201509265SA (en) | Avoiding narcolepsy risk in influenza vaccines | |
| ZA201409124B (en) | Reassortant btv and ahsv vaccines | |
| PL2958935T3 (pl) | Szczepionka | |
| AP2015008615A0 (en) | Vaccines against pregnancy-associated malaria | |
| GB201301119D0 (en) | Viral vaccines | |
| PL2911688T3 (pl) | Szczepionki zapewniające ochronę krzyżową przeciwko salmonelli | |
| GB201210226D0 (en) | Vaccine | |
| GB201202090D0 (en) | Vaccine | |
| ZA201508215B (en) | Avoiding narcolepsy risk in influenza vaccines | |
| DK2846829T3 (en) | Vaccine combinations | |
| GB201320646D0 (en) | Vaccine | |
| GB201315556D0 (en) | Vaccine |